H. Jack West, MD

H. Jack West, MD, thoracic oncologist at the Swedish Cancer Institute of Swedish Medical Center, discusses the data with atezolizumab (Tecentriq) and pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). West says that the choice of treatment is likely best left to the judgement of the physician and patient. 

H. Jack West, MD, thoracic oncologist, Swedish Cancer Institute at Swedish Medical Center, discusses how he treats patients with advanced lung cancer who do not have actionable oncogenic drivers. 

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses appropriate treatment for patients with stage IV adenocarcinoma who do not harbor oncogenic drivers.

H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).